Hydroxyurea for the treatment of sickle cell anemia - PubMed (original) (raw)
Review
. 2008 Mar 27;358(13):1362-9.
doi: 10.1056/NEJMct0708272.
Affiliations
- PMID: 18367739
- DOI: 10.1056/NEJMct0708272
Review
Hydroxyurea for the treatment of sickle cell anemia
Orah S Platt. N Engl J Med. 2008.
No abstract available
Comment in
- Hydroxyurea for sickle cell anemia.
Naina HV, Harris S. Naina HV, et al. N Engl J Med. 2008 Jul 3;359(1):98; author reply 98-9. doi: 10.1056/NEJMc080902. N Engl J Med. 2008. PMID: 18596283 No abstract available. - Hydroxyurea for sickle cell anemia.
Bachmeyer C, Aractingi S, Lionnet F. Bachmeyer C, et al. N Engl J Med. 2008 Jul 3;359(1):98; author reply 98-9. N Engl J Med. 2008. PMID: 18609755 No abstract available.
Similar articles
- Hydroxyurea for sickle cell anemia.
Bachmeyer C, Aractingi S, Lionnet F. Bachmeyer C, et al. N Engl J Med. 2008 Jul 3;359(1):98; author reply 98-9. N Engl J Med. 2008. PMID: 18609755 No abstract available. - Hydroxyurea and new agents for the treatment of sickle cell disease.
Rodgers GP. Rodgers GP. Clin Adv Hematol Oncol. 2004 Nov;2(11):713-5. Clin Adv Hematol Oncol. 2004. PMID: 16163257 No abstract available. - Hydroxyurea in very young children with sickle cell anemia is not a cure-all.
Powars DR. Powars DR. J Pediatr. 2001 Dec;139(6):763-4. doi: 10.1067/mpd.2001.120093. J Pediatr. 2001. PMID: 11743496 No abstract available. - Mechanism of action of hydroxyurea in the management of sickle cell anemia in adults.
Charache S. Charache S. Semin Hematol. 1997 Jul;34(3 Suppl 3):15-21. Semin Hematol. 1997. PMID: 9317197 Review. - Hydroxyurea therapy: improving the lives of patients with sickle cell disease.
Anderson N. Anderson N. Pediatr Nurs. 2006 Nov-Dec;32(6):541-3. Pediatr Nurs. 2006. PMID: 17256291 Review.
Cited by
- A zinc-finger transcriptional activator designed to interact with the gamma-globin gene promoters enhances fetal hemoglobin production in primary human adult erythroblasts.
Wilber A, Tschulena U, Hargrove PW, Kim YS, Persons DA, Barbas CF 3rd, Nienhuis AW. Wilber A, et al. Blood. 2010 Apr 15;115(15):3033-41. doi: 10.1182/blood-2009-08-240556. Epub 2010 Feb 26. Blood. 2010. PMID: 20190190 Free PMC article. - Challenges in the treatment of melanoma with BRAF and MEK inhibitors in patients with sickle cell disease: case report and review of the literature.
Diamantopoulos PT, Anastasopoulou A, Dimopoulou M, Samarkos M, Gogas H. Diamantopoulos PT, et al. Ther Adv Hematol. 2023 Mar 15;14:20406207231155991. doi: 10.1177/20406207231155991. eCollection 2023. Ther Adv Hematol. 2023. PMID: 36936358 Free PMC article. - Genetic modifiers of HbF and response to hydroxyurea in sickle cell disease.
Green NS, Barral S. Green NS, et al. Pediatr Blood Cancer. 2011 Feb;56(2):177-81. doi: 10.1002/pbc.22754. Epub 2010 Sep 9. Pediatr Blood Cancer. 2011. PMID: 20830771 Free PMC article. Review. - Hydroxyurea Optimization through Precision Study (HOPS): study protocol for a randomized, multicenter trial in children with sickle cell anemia.
Meier ER, Creary SE, Heeney MM, Dong M, Appiah-Kubi AO, Nelson SC, Niss O, Piccone C, Quarmyne MO, Quinn CT, Saving KL, Scott JP, Talati R, Latham TS, Pfeiffer A, Shook LM, Vinks AA, Lane A, McGann PT. Meier ER, et al. Trials. 2020 Nov 27;21(1):983. doi: 10.1186/s13063-020-04912-z. Trials. 2020. PMID: 33246482 Free PMC article. - Decreased fetal hemoglobin over time among youth with sickle cell disease on hydroxyurea is associated with higher urgent hospital use.
Green NS, Manwani D, Qureshi M, Ireland K, Sinha A, Smaldone AM. Green NS, et al. Pediatr Blood Cancer. 2016 Dec;63(12):2146-2153. doi: 10.1002/pbc.26161. Epub 2016 Aug 30. Pediatr Blood Cancer. 2016. PMID: 27573582 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Molecular Biology Databases